Establishment of prediction model of biologics and small molecular agents for patients with ulcerative colitis using longitudinal data

Asan Medical Center0 个研究点目标入组 300 人开始时间: 待定最近更新: 2023年1月10日

试验速览

暂无简介。

•Patients with confirmed ulcerative colitis (at the study center or other hospitals) and who are going to start TNF inhibitors, vedolizumab, ustekinumab, or tofacitinib therapy (at the study center). Patients who provide an informed consent will be enrolled in this study.
•- Diagnostic criteria for ulcerative colitis
•1) Having a), b), or c) for 4 weeks or longer: a) Diarrhea b) mucoid and bloody stool, c) a) + b)
•2) Typical colonoscpic or sigmoidoscopic features (diffuse granular mucosa, friability, and mucosal ulcerations involving rectum with a continuous pattern) or typical radiologic features (continuous granular mucosa or ulcers)
•3) Typical histologic features of colon showing chronic inflammation (structural change of crypt and/or basal lymphoplasmacytosis)

•- Not Korean ethnicity by the family history
•- Inflammatory bowel disease (IBD) unclassified (IBD-U): IBD limited to colorectum, which is having characteristics of both ulcerative colitis and Crohn's disease. IBD-U is diagnosed when it is difficult to be classified into ulcerative colitis or Crohn's disease based on clinical features, endoscopic features, radiologic features, pathologic features and overall assessment of treating physicians.

发起方